TY  - JOUR
AU  - Gambichler, Thilo
AU  - Hyun, Julia
AU  - Oellig, Frank
AU  - Becker, Jürgen C
AU  - Kreuter, Alexander
TI  - Immune checkpoint inhibitors for children with xeroderma pigmentosum and advanced cutaneous squamous cell carcinoma: A case presentation and brief review.
JO  - Journal der Deutschen Dermatologischen Gesellschaft
VL  - 23
IS  - 3
SN  - 1610-0379
CY  - Berlin
PB  - Wiley-Blackwell
M1  - DKFZ-2025-00507
SP  - ddg.15648
PY  - 2025
N1  - 303-308 / Mini-review
AB  - Patients with xeroderma pigmentosum (XP) frequently develop skin cancers early in life, including cutaneous squamous cell carcinoma (cSCC). The median age of death is 32 years and 60
KW  - Humans
KW  - Xeroderma Pigmentosum: complications
KW  - Xeroderma Pigmentosum: drug therapy
KW  - Male
KW  - Child
KW  - Skin Neoplasms: drug therapy
KW  - Skin Neoplasms: pathology
KW  - Immune Checkpoint Inhibitors: therapeutic use
KW  - Immune Checkpoint Inhibitors: adverse effects
KW  - Carcinoma, Squamous Cell: drug therapy
KW  - Carcinoma, Squamous Cell: pathology
KW  - Antibodies, Monoclonal, Humanized: therapeutic use
KW  - Antibodies, Monoclonal, Humanized: adverse effects
KW  - Lymphatic Metastasis: pathology
KW  - DNA repair defects (Other)
KW  - cemiplimab (Other)
KW  - childhood (Other)
KW  - genodermatoses (Other)
KW  - geno‐photodermatoses (Other)
KW  - keratoacanthoma (Other)
KW  - nivolumab (Other)
KW  - pembrolizumab (Other)
KW  - Immune Checkpoint Inhibitors (NLM Chemicals)
KW  - cemiplimab (NLM Chemicals)
KW  - Antibodies, Monoclonal, Humanized (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40052589
C2  - pmc:PMC11886998
DO  - DOI:10.1111/ddg.15648
UR  - https://inrepo02.dkfz.de/record/299566
ER  -